Siegel M, Lee SL: The epidemiology of systemic lupus erythematosus ... Takayasu V, Bonfa E, Levy NM, Kumeda C, Daud RM, Cossermelli W: Systemic lupus erythematosus in the aged: clinical and ...

Systemic lupus is the most common form of lupus—it’s what most people mean when they refer to “lupus.” Systemic lupus can be mild or severe. Cutaneous lupus erythematosus This form of lupus is limited ...

Thousands of passionate people with lupus and those who care about the cause will join together Saturday, October 19 at the Intrepid Museum ...

Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN). Gazyva is an engineered humanized monoclonal antibody ...

After collecting a handful of oncology approvals since its first leukemia nod in 2013, Roche’s Biogen-partnered Rituxan successor, Gazyva, is chasing new horizons in active lupus nephritis.

Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis The REGENCY study met its primary endpoint, demonstrating ...

Sept 24 (Reuters) - Biogen (BIIB.O), opens new tab and Belgian partner UCB (UCB.BR), opens new tab said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in ...

Roche RHHBY announced positive top-line data from a late-stage study of its marketed drug, Gazyva/Gazyvaro (obinutuzumab), to treat patients with active lupus nephritis (LN). The phase III REGENCY ...

Now, the company has hit the brakes on its phase 2b study of the drug in lupus nephritis following four patient fatalities. An independent data monitoring committee (IDMC) recommended suspending ...